Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445792 · ClinicalTrials.gov registry record · NA
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 4,284
- Enrollment target
NCT04445792 is a NA study that has completed, run by Duke University. The registered enrollment target is 4,284 participants.
The verdict
NCT04445792, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,284 participants
- Enrollment target
Study Summary
This is a Master Protocol Screening record. This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial. Participants can enroll in only one of the three trials. Each trial is listed individually on clinicaltrials.gov and includes "PRO00104948" within the Unique Protocol ID: PRO00104948\_A - Acute Pain Trial - NCT05966129 PRO00104948\_B - Chronic Pain Trial - NCT05966142 PRO00104948\_C - Depression Trial - NCT05966155 Acute Pain Trial: A prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided post-surgical opioid therapy (Intervention arm) or standard care and pharmacogenetic testing after 6 months (Control arm). The investigators will test the hypothesis that pharmacogenetic testing and genotype guided pain management therapy improves pain control after surgery in participants who's body processes some pain medicines slower than normal. Chronic Pain Trial: A prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided opioid therapy (Intervention arm) or standard care with 6-month delayed pharmacogenetic testing (Control arm). The investigators will test the hypothesis that pharmacogenetic testing and genotype guided pain therapy improves pain control after surgery in participants who's body processes some pain medicines slower than normal. Depression: A prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided anti-depressant therapy (Intervention arm) or
Interventions
- OTHER Pharmacogenetic testing
- OTHER Clinical decisions support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,284 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2024-05-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04445792
The ClinicalTrials.gov registry entry for NCT04445792 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4,284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenetic testing is the first listed.
NCT04445792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04445792 about?
NCT04445792 is a clinical study titled "A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)". This is a Master Protocol Screening record. This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depres...
What is the current status of trial NCT04445792?
This trial is currently completed. It is a NA study. The enrollment target is 4,284 participants. The study started on 2021-02-24. Estimated completion is 2024-05-10.
What interventions are being tested in trial NCT04445792?
The interventions under investigation include: Pharmacogenetic testing (OTHER), Clinical decisions support (OTHER).
Who is sponsoring clinical trial NCT04445792?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.